# A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I 

Source: https://onco.cc/trials/nct07513376/  
OnCo record `nct07513376` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Intismeran autogene in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014) is a phase 3 interventional study registered as NCT07513376 by Merck Sharp & Dohme LLC, with 876 participants planned, started 2026-05-04 and due to reach its primary completion in 2034-08-22. Interventions recorded: Intismeran, Pembrolizumab coformulated with berahyaluronidase alfa, Placebo. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07513376
- Phase: 3
- Setting: A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 876

## Sources

- ClinicalTrials.gov NCT07513376: https://clinicaltrials.gov/study/NCT07513376

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Intismeran autogene](https://onco.cc/drugs/intismeran-autogene/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct07513376.json